251 related articles for article (PubMed ID: 29138547)
1. Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study.
Fujimoto K; Yamazaki H; Ura M; Kitaguchi Y
Int J Chron Obstruct Pulmon Dis; 2017; 12():3195-3201. PubMed ID: 29138547
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.
Kawachi S; Fujimoto K
Int J Chron Obstruct Pulmon Dis; 2019; 14():1167-1176. PubMed ID: 31213796
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
Rhee CK; Park HY; Park JW; Lee JH; Kim TH; Lee SW; Jung JY; Kim S; Hwang YI; Jung KS
Trials; 2017 Feb; 18(1):80. PubMed ID: 28228162
[TBL] [Abstract][Full Text] [Related]
4. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
Kardos P; Hagedorn-Peinz I
Int J Chron Obstruct Pulmon Dis; 2018; 13():69-77. PubMed ID: 29317812
[TBL] [Abstract][Full Text] [Related]
5. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
Derom E; Brusselle GG; Joos GF
Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Vogelmeier CF; Gaga M; Aalamian-Mattheis M; Greulich T; Marin JM; Castellani W; Ninane V; Lane S; Nunez X; Patalano F; Clemens A; Kostikas K;
Respir Res; 2017 Jul; 18(1):140. PubMed ID: 28720132
[TBL] [Abstract][Full Text] [Related]
8. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium
Beaulieu J; Jensen D; O'Donnell DE; Brouillard C; Tracey L; Vincent S; Nadreau É; Bernard E; Bernard S; Maltais F
Ther Adv Respir Dis; 2020; 14():1753466620939507. PubMed ID: 32663102
[TBL] [Abstract][Full Text] [Related]
9. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
Anzueto AR; Vogelmeier CF; Kostikas K; Mezzi K; Fucile S; Bader G; Shen S; Banerji D; Fogel R
Int J Chron Obstruct Pulmon Dis; 2017; 12():1325-1337. PubMed ID: 28496316
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
[TBL] [Abstract][Full Text] [Related]
11. Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease.
Inui N; Matsushima S; Kato S; Yasui H; Kono M; Fujisawa T; Enomoto N; Nakamura Y; Toyoshima M; Suda T
Int J Chron Obstruct Pulmon Dis; 2015; 10():1139-46. PubMed ID: 26124653
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
Hashimoto S; Ikeuchi H; Murata S; Kitawaki T; Ikeda K; Banerji D
Int J Chron Obstruct Pulmon Dis; 2016; 11():2543-2551. PubMed ID: 27785010
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
Chan MC; Tan EC; Yang MC
Int J Chron Obstruct Pulmon Dis; 2018; 13():1079-1088. PubMed ID: 29670344
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences.
Ohno T; Wada S; Hanada S; Sawaguchi H; Muraki M; Tohda Y
Int J Chron Obstruct Pulmon Dis; 2014; 9():107-14. PubMed ID: 24489464
[TBL] [Abstract][Full Text] [Related]
16. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
18. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
19. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
Greulich T; Kostikas K; Gaga M; Aalamian-Mattheis M; Lossi NS; Patalano F; Nunez X; Pagano VA; Fogel R; Vogelmeier CF; Clemens A
Int J Chron Obstruct Pulmon Dis; 2018; 13():1229-1237. PubMed ID: 29713156
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
Jiang FM; Liang ZA; Zheng QL; Wang RC; Luo J; Li CT
Lung; 2013 Apr; 191(2):135-46. PubMed ID: 23306410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]